Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Roland Ott who wrote (2838)	1/7/1999 6:47:00 PM
From: EZLibra	Read Replies (1) \| Respond to of 3702

Hi Roland, it's been a long time. My opinion hasn't changed on HIV. I've known it since its IPO. I was surprised Geert got involved with Ziegleman and company, he was always right on top of the money. It takes one to know one? ONXX has always been interesting. I can't help but think that viral vectors have a role in cancer therapeutics. There will never be one single cure for many cancers and a lot of combinations will be used. I would like to see how their vectors do as frontline therapy. I assume you meant to compare TNT and not the VTAs. TNT is now in a Phase II involving frontline therapy for multiforme glioblastoma and astrocytoma. The Phase I only took six months. And a Phase I-II is recruiting at the Mexico NIH for liver, prostate and pancreatic cancers. We have heard that nine different cancers have successfuly been treated in China, Israel, and Mexico. We know brain and prostate cancers have been successfully treated stateside. Yes, to answer your question, I believe TNT is far ahead of HIV and ONXX and probably any other pandemic cancer therapy. Not to mention Oncolym, not a word about which has been uttered since some remarkable slides were shown at a NY luncheon last June. Pay attention to those Swiss companies, Roland, they're hungry and they all know PSI.